Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Policy / Regulatory

China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management

Fineline Cube Aug 7, 2024

The National Medical Products Administration (NMPA) of China has issued a new set of regulations...

Company Deals

JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies

Fineline Cube Aug 7, 2024

Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...

Company Deals

Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases

Fineline Cube Aug 7, 2024

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered...

Company

Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance

Fineline Cube Aug 7, 2024

Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...

Company

Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales

Fineline Cube Aug 7, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...

Company Deals

Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia

Fineline Cube Aug 7, 2024

Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...

Company Deals

CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology

Fineline Cube Aug 7, 2024

CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...

Company Deals

Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor

Fineline Cube Aug 7, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...

Company Drug

Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China

Fineline Cube Aug 7, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...

Company Deals

Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil

Fineline Cube Aug 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...

Company Deals

Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079

Fineline Cube Aug 7, 2024

Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...

Company

Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare

Fineline Cube Aug 7, 2024

Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...

Company Drug

Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment

Fineline Cube Aug 6, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...

Company Medical Device

Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital

Fineline Cube Aug 6, 2024

Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...

Company Drug

Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction

Fineline Cube Aug 6, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Company Drug

Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Aug 6, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Drug

Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar

Fineline Cube Aug 6, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...

Company Drug

Luye Pharma’s LY03020 Receives NMPA Approval for Schizophrenia and Alzheimer’s Psychosis Treatment

Fineline Cube Aug 6, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that it has received...

Company Drug

CMS’s Methotrexate Injection Gains NMPA Approval for Active Rheumatoid Arthritis Treatment

Fineline Cube Aug 6, 2024

China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...

Company Deals

Northeast Pharmaceutical to Acquire Majority Stake in Cell Therapy Specialist Dingcheng Taiyuan

Fineline Cube Aug 6, 2024

Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire...

Posts pagination

1 … 363 364 365 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.